Region
CDMOs in Europe
Compare European CDMOs with EMA-compliant facilities across Germany, Switzerland, Ireland, and the broader EU. Filter by specialization, scale, and regulatory approvals.
926 companies listed
European CDMO Manufacturing
Europe is the second-largest pharma manufacturing region globally, with particular strengths in biologics, API synthesis, and sterile manufacturing. Germany leads in both volume and technological capability, followed by Switzerland (home to major CDMO headquarters), Ireland (a biologics manufacturing hub driven by favorable tax policy), and Italy (strong in API and generics).
EMA regulation provides mutual recognition advantages. A GMP certificate from one EU member state is recognized across the bloc, simplifying multi-market filings. The EMA also maintains Mutual Recognition Agreements (MRAs) with regulators in the US, Canada, Australia, Japan, and other markets, meaning European GMP inspections are often accepted by foreign authorities.
How does pricing compare? European CDMOs typically cost 10-30% more than Asian alternatives but offer shorter lead times for European and US sponsors, stronger IP protection, and established regulatory relationships. For high-value biologics and specialty products, the total cost of quality often favors European manufacturing.
Browse Europe CDMOs by country
Every country below has its own page with a ranked CDMO list, a country-zoomed facilities map, and the local regulatory picture. Counts are live manufacturing-site totals.
Companies (926)
Lykan Bioscience
United Kingdom
Lykan Bioscience is a CDMO focused exclusively on cell-based therapies, located in Hopkinton, Massachusetts. They have merged with RoslinCT (Scotland-based) to form a global advanced therapies CDMO. Their facility is purpose-built for cGMP cell therapy manufacturing, featuring ISO 7 cleanrooms. They announced a 90% capacity expansion and added six new cGMP manufacturing suites. They have been granted a MIA License for cGMP manufacturing.
Cell & Gene TherapyCell TherapyAseptic Processing
Lyomark Pharma GmbH
Germany
Lyomark Pharma GmbH is a German CDMO specializing in sterile medicinal products. They organize contract manufacturing based on dossiers they compile and maintain, and offer regulatory services. Through their subsidiary Lyocontract, they operate a state-of-the-art pharmaceutical manufacturing site. They have 39 FDA-approved products across injectable, oral solid, and liquid dosage forms. The company focuses on niche indications for the hospital market with global distribution.
Frequently Asked Questions
What are the advantages of European CDMOs?+
Strong regulatory framework with EMA GMP compliance recognized globally. Mutual Recognition Agreements reduce the need for duplicate inspections. Deep talent pool in biotechnology and chemistry. Proximity to European markets and established distribution networks. Strong intellectual property protection under EU law. Many European CDMOs also hold FDA registration for US-market products.
How does EMA regulation compare to FDA?+
Both agencies enforce cGMP standards, but the processes differ. EMA uses a centralized procedure for EU-wide marketing authorization with national agencies conducting GMP inspections. FDA directly inspects manufacturing facilities. The EMA-FDA MRA means each agency can rely on the other's inspection findings, reducing duplication. Key difference: EMA requires a Qualified Person (QP) for batch release -- a role that does not exist in the US system.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
